AUPH

Even though Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) posted strong earnings recently, the stock hasn't reacted in a large way. We think that investors might be worried about the foundations the earnings are built on. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Many investors haven't heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company's profit is backed up by free cash flow (FCF) during a given period. The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. The ratio shows us how much a company's profit exceeds its FCF. As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future". Over the twelve months to March 2026, Aurinia Pharmaceuticals recorded an accrual ratio of 1.16. Ergo, its free cash flow is significantly weaker than its profit. As a general rule, that bodes poorly for future profitability. To wit, it produced free cash flow of US$167m during the period, falling well short of its reported profit of US$298.2m. At this point we should mention that Aurinia Pharmaceuticals did manage to increase its free cash flow in the last twelve months Importantly, we note an unusual tax situation, which we discuss below, has impacted the accruals ratio. This would partially explain why the accrual ratio was so poor. One positive for Aurinia Pharmaceuticals shareholders is that it's accrual ratio was significantly better last year, providing reason to believe that it may return to stronger cash conversion in the future. As a result, some shareholders may be looking for stronger cash conversion in the current year. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. Moving on from the accrual ratio, we note that Aurinia Pharmaceuticals profited from a tax benefit which contributed U...

ROCKVILLE, Maryland & EDMONTON, Alberta, May 07, 2026--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress. Financial Results Total Revenue: For the three months ended March 31, 2026, total revenue was $77.7 million, up 24% from $62.5 million in the same period of 2025. Net Product Sales: For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $73.6 million, up 23% from $60.0 million in the same period of 2025. License, Collaboration and Royalty Revenue: For the three months ended March 31, 2026, license, collaboration and royalty revenue from Aurinia’s collaboration partner, Otsuka, was $4.1 million, up 64% from $2.5 million in the same period of 2025. Net Income: For the three months ended March 31, 2026, net income was $34.4 million, up 48% from $23.3 million in the same period of 2025. Diluted Earnings per Share: For the three months ended March 31, 2026, diluted earnings per share was $0.25, up 56% from $0.16 in the same period of 2025. Cash Flows from Operating Activities: For the three months ended March 31, 2026, cash flows from operating activities were $32.6 million, up 2408% from $1.3 million in the same period of 2025. Cash Position As of March 31, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $378.8 million, compared to $398.0 million at December 31, 2025. For the three months ended March 31, 2026, cash outflows from financing activities were $53.7 million, which included the repurchase of 2.5 million of the Company’s common shares for $36.2 million and tax withholding payments related to net settlements of equity awards of $14.6 million. 2026 Total Revenue and Net Product Sales Guidance Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025. "Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases," stated Kevin Tang, Chief Executive Officer. "LUPKYNIS is emerging as a standard-of-care treatment for lupus nephritis, and aritinercept, no...

EDMONTON, Alberta (AP) — EDMONTON, Alberta (AP) — Aurinia Pharmaceuticals Inc. (AUPH) on Thursday reported first-quarter earnings of $34.4 million. The Edmonton, Alberta-based company said it had net income of 25 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 18 cents per share. The biotechnology company posted revenue of $77.7 million in the period, also surpassing Street forecasts. Three analysts surveyed by Zacks expected $77.4 million. Aurinia expects full-year revenue in the range of $315 million to $325 million. Aurinia shares have risen roughly 2% since the beginning of the year. The stock has more than doubled in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AUPH at https://www.zacks.com/ap/AUPH

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +38.89%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.21 per share when it actually produced earnings of $0.26, delivering a surprise of +23.81%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Aurinia, which belongs to the Zacks Medical - Drugs industry, posted revenues of $77.71 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 0.39%. This compares to year-ago revenues of $62.47 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Aurinia shares have added about 1.9% since the beginning of the year versus the S&P 500's gain of 7.6%. While Aurinia has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Aurinia was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news from United Therapeutics and Biogen, as well as updates from Eli Lilly, Novo Nordisk and Aurinia Pharmaceuticals that you may have missed. Shares of United Therapeutics were up nearly 15% Monday morning on data from a late-stage clinical trial that assessed the company’s already-marketed drug Tyvaso in patients with a rare lung condition known as idiopathic pulmonary fibrosis. Another, similar trial had previously hit its main goal. According to United, the newer results — from a study titled TETON-1 — were even better. After a year of treatment, patients given Tyvaso showed an absolute change in “forced vital capacity” of 130.1 mL. FVC is a key test for potential IPF treatments, as it measures lung health by quantifying how much air a patient can forcefully exhale after taking a deep breath. Tyvaso is currently used for a lung-related illness called pulmonary arterial hypertension. The data from TETON-1 should “favorably shift the Tyvaso narrative away from the nuances” of the competitive PAH market and towards the “more ‘green field’ blockbuster opportunity” of IPF, according to Leerink Partners analyst Roanna Ruiz. Biogen on Monday said the Food and Drug Administration approved a higher-dose version of the company’s spinal muscular atrophy drug Spinraza. The new regimen will be available in the coming weeks, according to Biogen, and allows for an accelerated loading phase. Two 50 milligram doses are administered 14 days apart, followed by 28 milligram maintenance dose injections every four months thereafter. The approval should keep Biogen’s SMA franchise “durable” and serve as a bridge until the company’s next-generation medicine, “salanersen,” comes to market, wrote Jefferies analyst Andrew Tsai in a note to clients. Tsai added that his team expects the Spinraza franchise, which generated roughly $1.5 billion in sales last year, to “remain resilient (or even grow)” despite the SMA market possibly getting more crowded over the next couple years. The FDA has approved Novo Nordisk’s Awiqli as an adjunct treatment to diet and exercise to improve blood sugar control in adults with Type 2 diabetes. The FDA based its decision on data from four studies that enrolled nearly 2,700 patients...

In late February 2026, Aurinia Pharmaceuticals reported fourth-quarter 2025 revenue of US$77.11 million and full-year revenue of US$283.06 million, alongside a jump in net income to US$287.2 million and basic earnings per share of US$2.14 from continuing operations. The company also issued 2026 guidance calling for total revenue of US$315 million to US$325 million and net product sales of US$305 million to US$315 million, signaling management’s confidence in ongoing LUPKYNIS momentum and operational execution. We’ll now examine how this combination of very large year-on-year earnings growth and double-digit 2026 revenue guidance affects Aurinia’s investment narrative. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. To own Aurinia, you need to believe LUPKYNIS can support a durable, profitable franchise while the pipeline, led by aritinercept, matures into a second growth pillar. The latest results, with a sharp jump in 2025 earnings and management guiding to US$315–325 million in 2026 revenue, reinforce the near term earnings story but do not remove the core risk of heavy dependence on a single drug and ongoing scrutiny of LUPKYNIS exclusivity. Among recent announcements, the 2026 revenue and net product sales guidance stands out as most relevant. Management’s outlook for 11–15% total revenue growth and 12–16% LUPKYNIS sales growth ties directly into the key catalyst of continuing adoption supported by clinical guidelines, while also highlighting the tension with the main risk factor: how long LUPKYNIS can remain the primary engine before competition, pricing pressure, or pipeline execution start to matter more. Yet beneath the strong 2025 earnings and upbeat 2026 guidance, investors should be aware that... Read the full narrative on Aurinia Pharmaceuticals (it's free!) Aurinia Pharmaceuticals' narrative projects $386.4 million revenue and $141.3 million earnings by 2028. This requires 14.1% yearly revenue growth and a $80.7 million earnings increase from $60.6 million today. Uncover how Aurinia Pharmaceuticals' forecasts yield a $16.67 fair value, a 17% upside to its current price. Some of the most optimistic analy...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is one of the best cheap biotech stocks to buy now. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and twelve months ended December 31, 2025, on February 26, 2026. It reported that total revenue for the three and twelve months was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million in the prior year periods, respectively. Net product sales of LUPKYNIS, which is the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $74.2 million and $271.3 million for the three and twelve months, up 29% and 25%, respectively, compared to $57.6 million and $216.2 million for the same periods of 2024, respectively. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) further reported that it has cash, cash equivalents, restricted cash, and investments of $398.0 million as of December 31, 2025, compared to $358.5 million in the prior year period. It also repurchased 12.2 million of its common shares for $98.2 million in the year 2025. For 2026, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) expects total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and net product sales of $305 million to $315 million, up 12% to 16% compared to 2025. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is a clinical-stage bio-pharmaceutical company involved in the research, development, and commercialization of therapeutic drugs. While we acknowledge the potential of AUPH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

This article first appeared on GuruFocus. Release Date: February 26, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) reported a 29% increase in total revenue for Q4 2025 compared to the same period in 2024. Net product sales of Lukiness grew by 25% year-over-year, indicating strong market demand. The company achieved a significant increase in net income for Q4 2025, up 14,957% from the previous year, primarily due to the release of its valuation allowance on deferred tax assets. Cash flows from operating activities increased by 52% in Q4 2025 compared to Q4 2024, reflecting improved operational efficiency. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has initiated a clinical study of Ari intercept in one autoimmune disease and plans to start another in the first half of 2026, showing progress in their pipeline development. The guidance for 2026 appears conservative despite strong Q4 2025 performance, raising questions about future growth assumptions. The company terminated the phase 3 and open-label studies in the vocal study due to recruitment challenges, indicating potential setbacks in clinical development. There is uncertainty regarding the competitive impact of new entrants like Gazaga in the lupus nephritis market. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) faces challenges in achieving global market penetration similar to the US due to varying pricing and reimbursement landscapes. The company is not providing specific commercial metrics, which may limit transparency for investors. Warning! GuruFocus has detected 7 Warning Signs with CPK. Is AUPH fairly valued? Test your thesis with our free DCF calculator. Q: Your issued guidance for 2026 seems somewhat conservative given the 4Q run rate. What are some specifics informing the commercial outlook and what are you seeing in the first two months of this year? A: Our strategy for the commercial business of Luinis remains consistent, focusing on the efficacy of the product in treating lupus nephritis and reducing proteinuria. We leverage expanded data sets and guidelines to promote early and aggressive treatment. As for the first two months of the year, we are not providing specific guidance but suggest looking at Q1 of 2025 for trends. Q: You recently terminated the phase 3 and open-label studies in the vocal st...

LUPKYNIS net product sales grew 25% year-over-year in 2025, driven by consistent patient adherence and stable commercial pricing dynamics. Management attributes commercial success to the adoption of ACR and EULAR guidelines, which advocate for aggressive proteinuria reduction and earlier diagnostic intervention. The company recorded a significant net income spike due to a $173 million income tax benefit for the full year from the release of valuation allowances on deferred tax assets. Strategic focus has shifted toward rheumatologists, who now represent a slightly larger share of the prescriber base than nephrologists due to their role in early-stage SLE diagnosis. Operational efficiency and revenue growth resulted in a 206% increase in annual cash flows from operating activities, reaching $135.7 million. The company executed a capital allocation strategy that reduced fully diluted shares outstanding from 149.8 million to 139.7 million through share repurchases. 2026 net product sales guidance of $305 million to $315 million assumes 12% to 16% growth, factoring in historical trends and new market competition. Management plans to disclose specific autoimmune indications for the aritinercept clinical program in the second quarter of 2026. A second clinical study for aritinercept is scheduled to initiate in the first half of 2026, targeting a separate B-cell mediated autoimmune disease. The company intends to negotiate with the FDA regarding pediatric commitments following the termination of the VOCAL pediatric study due to recruitment challenges. Future R&D exploration may include combining T-cell targeted LUPKYNIS with B-cell therapies to address breakthrough proteinuria in stable SLE patients. The Phase III VOCAL pediatric study was terminated due to technical recruitment difficulties; management noted the pediatric LN market is small with limited business impact. Phase I data for aritinercept showed low-titer anti-drug antibodies (ADAs) at doses above 25mg, though management reported no impact on safety or pharmacokinetics. International revenue from Otsuka partnerships in Europe and Japan is expected to remain a minor contributor due to lower pricing and varied reimbursement hurdles compared to the U.S. The release of a $173 million valuation allowance reflects management's confidence in the long-term profitability and realization of deferred tax assets. O...

LUPKYNIS-driven growth and 2026 guidance: Q4 revenue rose to $77.1M (+29%) and full-year 2025 revenue was $283.1M (+20%; +26% excluding a $10M Japan milestone) with LUPKYNIS sales of $271.3M, and management guided 2026 revenue of $315–325M (net product sales $305–315M). Net income surge tied to tax benefit and buybacks: Q4 net income was $210.8M (FY $287.2M) largely driven by a ~$175M valuation-allowance release tax benefit; Aurinia ended 2025 with ~$398M in cash and repurchased 12.2M shares for $98.2M. Pipeline and commercial outlook: Aurinia has started clinical development of the dual BAFF/APRIL inhibitor aritinercept with two studies planned in H1 2026 (indications to be disclosed in Q2), terminated its pediatric VOCAL study due to recruitment issues, and says new competition hasn’t had a near-term impact while guideline changes may expand diagnosis and treatment. Interested in Aurinia Pharmaceuticals Inc? Here are five stocks we like better. These 2 Healthcare Stocks Have Doubled in 2023 Aurinia Pharmaceuticals (NASDAQ:AUPH) reported fourth-quarter and full-year 2025 results on its latest earnings call, highlighting continued growth from its lupus nephritis therapy LUPKYNIS and outlining revenue expectations for 2026. Management also provided updates on its clinical-stage biologic candidate aritinercept and discussed commercial dynamics in lupus nephritis, including evolving guidelines and competitive developments. Chief Financial Officer Joe Miller said total revenue in the fourth quarter of 2025 rose to $77.1 million, up 29% from $59.9 million in the same period of 2024. Net product sales of LUPKYNIS in the quarter were $74.2 million, also up 29% from $57.6 million a year earlier. → SoundHound’s New Sales Assist Agent Put Voice AI Back in the Spotlight Aurinia posted net income of $210.8 million for the fourth quarter, compared with $1.4 million in the prior-year quarter. Miller attributed a significant portion of the increase to an income tax benefit of $175.1 million, “primarily due to the release of its valuation allowance on deferred tax assets that the company now expects to realize.” Net income before income taxes was $35.7 million, up from $1.2 million a year earlier, and diluted earnings per share were $1.53 versus $0.01 in the fourth quarter of 2024. Cash flows from operating activities in the quarter totaled $45.7 million, up from $30.1 mill...

Aurinia Pharmaceuticals (AUPH) reported Q4 earnings Thursday of $1.53 per diluted share, up from $0.

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Aurinia Pharmaceuticals reported promising topline financial results for Q4 and full-year 2025. The company highlighted strong sales performance for its lead drug, LUPKYNIS. Aurinia initiated clinical studies for a new autoimmune therapy candidate, aritinercept. The updates reflect both commercial progress and continued pipeline activity in autoimmune disease. Aurinia Pharmaceuticals, listed as NasdaqGM:AUPH, is drawing attention after its latest update combined solid financial headlines with clear product and pipeline momentum. The stock last closed at $14.43, with a 1 year return of 81.5% and a 3 year return of 60.5%. For investors tracking autoimmune drug developers, this mix of revenue traction from LUPKYNIS and new clinical activity helps frame how Aurinia is positioned today. The initiation of aritinercept studies alongside LUPKYNIS sales progress gives you two main angles to watch: commercial execution and clinical development. How the company balances capital allocation between its marketed product and pipeline, and how that translates into future updates, may be important for investors following NasdaqGM:AUPH through 2026. Stay updated on the most important news stories for Aurinia Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Aurinia Pharmaceuticals. 3 things going right for Aurinia Pharmaceuticals that this headline doesn't cover. ✅ Price vs Analyst Target: At $14.43 against a consensus target of $16.67, Aurinia trades about 15% below analyst expectations. ✅ Simply Wall St Valuation: The shares are flagged as undervalued, trading 63.1% below an estimated fair value. ❌ Recent Momentum: The 30 day return of roughly 1.9% decline shows recent weakness despite the positive update. There is only one way to know the right time to buy, sell or hold Aurinia Pharmaceuticals. Head to Simply Wall St's company report for the latest analysis of Aurinia Pharmaceuticals's Fair Value. 📊 Strong LUPKYNIS sales and profitable 2025 results support the current business, while aritinercept adds a second potential growth pillar in autoimmune disease. 📊 Keep an eye on LUPKYNIS revenue trends, the P/E of 24.4 versus the 23.0 sector average, and any clinical milestones or safe...